1. Home
  2. FAX vs REPL Comparison

FAX vs REPL Comparison

Compare FAX & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FAX
  • REPL
  • Stock Information
  • Founded
  • FAX 1986
  • REPL 2015
  • Country
  • FAX United States
  • REPL United States
  • Employees
  • FAX N/A
  • REPL N/A
  • Industry
  • FAX Investment Managers
  • REPL Biotechnology: Pharmaceutical Preparations
  • Sector
  • FAX Finance
  • REPL Health Care
  • Exchange
  • FAX Nasdaq
  • REPL Nasdaq
  • Market Cap
  • FAX 619.2M
  • REPL 578.4M
  • IPO Year
  • FAX N/A
  • REPL 2018
  • Fundamental
  • Price
  • FAX $15.74
  • REPL $7.41
  • Analyst Decision
  • FAX
  • REPL Strong Buy
  • Analyst Count
  • FAX 0
  • REPL 6
  • Target Price
  • FAX N/A
  • REPL $20.00
  • AVG Volume (30 Days)
  • FAX 833.6K
  • REPL 1.1M
  • Earning Date
  • FAX 01-01-0001
  • REPL 05-19-2025
  • Dividend Yield
  • FAX 12.09%
  • REPL N/A
  • EPS Growth
  • FAX N/A
  • REPL N/A
  • EPS
  • FAX N/A
  • REPL N/A
  • Revenue
  • FAX N/A
  • REPL N/A
  • Revenue This Year
  • FAX N/A
  • REPL $31.16
  • Revenue Next Year
  • FAX N/A
  • REPL N/A
  • P/E Ratio
  • FAX N/A
  • REPL N/A
  • Revenue Growth
  • FAX N/A
  • REPL N/A
  • 52 Week Low
  • FAX $2.33
  • REPL $4.92
  • 52 Week High
  • FAX $2.84
  • REPL $17.00
  • Technical
  • Relative Strength Index (RSI)
  • FAX 60.69
  • REPL 37.53
  • Support Level
  • FAX $14.37
  • REPL $6.93
  • Resistance Level
  • FAX $15.59
  • REPL $8.54
  • Average True Range (ATR)
  • FAX 0.20
  • REPL 0.73
  • MACD
  • FAX 0.05
  • REPL -0.10
  • Stochastic Oscillator
  • FAX 98.41
  • REPL 14.24

About FAX abrdn Asia-Pacific Income Fund Inc.

Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Share on Social Networks: